JPRN-UMIN000007961招募中1 期
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancer - Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with refractory esophageal cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Past history of severe hypersensitivity 2. Positive for HIV antibody 3. Experience of autoimmune disease requiring treatment during 6 months preceding the day of consent 4. Use of steroids (more than 20 mg equivalent of prednisolone/day) or immunosuppressive drugs 5. Patients with following severe complications # severe heart disease or uncontrolled angina # Uncontrolled diabetes mellitus # Intestinal paresis or ileus # Active infections requiring antibiotics # Other severe complications 6. Pregnant or lactating women 7. Inappropriate for study entry judged by an attending physicians
研究者
相似试验
已完成
1 期
Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate CancerJPRN-UMIN000005246Mie University Graduate School of Medicine12
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
已完成
不适用
A study to evaluate the safety and tolerability of doxorubicin and durvalumab, in patients with advanced soft tissue sarcoma.KCT0003577Yonsei University Health System, Severance Hospital45
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
已完成
不适用
The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancerJPRN-UMIN000013378Kyoto Prefectural University of Medicine9